Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
+0.34%+1.12%+34.75%+61.06% 64.38B
+0.98%+2.68%+12.25%+82.98% 56.16B
+1.75%+2.01%+13.30%+103.69% 54.16B
-1.43%-1.17%+26.27%+52.86% 45.33B
-0.48%-2.80%+18.01%+117.99% 42.25B
+0.82%+1.37%+227.94%+922.41% 40.78B
-2.07%+42.73%+103.77%+88.74% 33.8B
-0.26%-2.57%+12.55%+45.18% 32.25B
-1.38%-3.01%+21.43%-12.04% 23.57B
Average -0.18%+4.50%+52.25%+162.54% 43.63B
Weighted average by Cap. +0.02%+3.60%+49.18%+161.40%
Logo Thallion Pharmaceuticals Inc.
Thallion Pharmaceuticals Inc is a Canada-based biotechnology company. The Company develops pharmaceutical products in the areas of infectious disease and oncology. Thallion Pharmaceuticals Inc's lead clinical program, Shigamabs, is a dual antibody product for the treatment of Shiga toxin-producing E. coli bacterial infections and has completed a Phase II clinical trial. The Company is a subsidiary of BELLUS Health.
Employees
-